Myfortic
(mycophenolate sodium)Phase 3Small molecule
NovartisMycophenolate sodium is used to prevent the body's immune system from rejecting transplanted organs, particularly kidneys. It's also used to treat certain autoimmune conditions like lupus.[1] Myfortic is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Myfortic is one of 140 small molecule programs targeting Uveitis. It is currently in Phase 3.
7
Indications
71
Total Trials
4
Active Trials
139
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
145 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Myfortic
NovartisPhase 3
Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Zyrtec
KKenvue Brands
Phase 3
Vumerity
BiogenPhase 3
Mayzent
NovartisPhase 3
Antihistamine
Arrowhead PharmaceuticalsPhase 3
Recombinant Zoster Vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
Tolebrutinib
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Kidney Transplant20 trials
Show 17 more trials
Renal Transplant11 trials
Show 8 more trials
Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients
Completed·—·Phase 4·NCT00443937·15 enrolled
Renal Transplant Recipients11 trials
Show 8 more trials
Efficacy and Safety3 trials
ESS3 trials
19 more indications
Liver Transplant2 trials
Safety and Efficacy2 trials
Gastrointestinal2 trials
Lupus Nephritis2 trials
The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
Terminated·—·Phase 3·NCT01015456·59 enrolled
Heart Transplant1 trial
Hematological Malignancies1 trial
Primary Sjogren's Syndrome1 trial
Steroid1 trial
Maintenance Therapy1 trial
Transplantation1 trial
Lupus1 trial
Autoimmune Disease1 trial
Transplant Recipient1 trial
Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
Completed·—·Phase 4·NCT00574197·11 enrolled
Recurrent Acute Myeloid Leukemia1 trial
Renal Allograft Recipients1 trial
Kidney Transplant Rejection1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mycophenolate sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]